Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascending single-dose phase 1 study of AJM300 (carotegrast methyl) in healthy adult males
jRCT1080224924Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial comparing AJM300 (carotegrast methyl) with Placebo (2 arms). Primary endpoints: Tolerability and safety of single ascending oral doses of AJM300, Pharmacokinetics of AJM300 and 1 more. Started Oct 2019; status: completed.
02
Drugs
firategrast
Beyond the preview
Go deeper on jRCT1080224924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224924.